araag2/HINT huggingface dataset:
Clinical trial NCT00728195 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: jnj-37822681, jnj-37822681, jnj-37822681, olanzapine, placebo
SMILES: FC1=C(F)C=C(CN2CCC(CC2)NC2=CC=C(N=N2)C(F)(F)F)C=C1, FC1=C(F)C=C(CN2CCC(CC2)NC2=CC=C(N=N2)C(F)(F)F)C=C1, FC1=C(F)C=C(CN2CCC(CC2)NC2=CC=C(N=N2)C(F)(F)F)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have been diagnosed with schizophrenia according to Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (295.10, 295.20, 295.30,
             295.60, 295.90) at least 1 year prior to screening

          -  Participants must be experiencing an acute (a quick and severe form of illness in its
             early stage) exacerbation of less than 6 months duration, with a Positive and Negative
             Syndrome Scale (PANSS) total score at screening between 70 and 120 inclusive and at
             baseline of between 60 and 120 inclusive

          -  Women of child bearing potential must have a negative urine pregnancy test at
             screening and baseline before receiving the study drug

          -  Participants must agree to voluntary hospitalization for a minimum of 14 days

          -  BMI (Body Mass Index) maximum 40 kilogram per meter square (kg/m^2), inclusive
             (BMI=weight/height^2)

        Exclusion Criteria:

          -  A DSM-IV axis I diagnosis other than schizophrenia

          -  A DSM-IV diagnosis of substance dependence within 6 months prior to screening
             evaluation

          -  Any clinically relevant medical condition that could potentially alter the absorption
             (the way a drug or other substance enters the body), metabolism, or excretion (the way
             that substances leave the body) of the study medication, such as Crohn's disease
             (serious inflammation of any part of the gastrointestinal tract), liver disease, or
             renal (pertaining to the kidneys) disease

          -  Relevant history of any significant and/or unstable cardiovascular (pertaining to the
             heart and blood vessels), respiratory, neurological (including seizures) or
             significant cerebrovascular (pertaining to brain and blood vessels), renal, hepatic,
             endocrine (pertaining to the glands that make hormones), or immunologic diseases

          -  History of neuroleptic malignant syndrome (high fever, rigid muscles, shaking,
             confusion, sweating more than usual, increased heart rate or blood pressure, or muscle
             pain or weakness)
Clinical trial NCT01020123 (phase 2, status: completed)
Conditions: type ii diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: azd1656, placebo, glipizide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  female of non-childbearing potential

          -  Treated with maximally tolerated dose of metformin (≥ 1500mg/day) for at least 10
             weeks prior to enrolment.

          -  Patients with HbA1c ≥ 7.5 but ≤ 10% at enrolment visit (Visit 1) can enter cohort
             1.Patients with HbA1c between >10 % and <12 % can enter the open-label arm with
             AZD1656 (cohort 2)

        Exclusion Criteria:

          -  Significant cardiovascular event within the last 6 months prior to enrolment or heart
             failure New York Heart Association (NYHA) class III-IV.

          -  Impaired renal function in terms of GFR<60 ml/min, based on Modification of Diet in
             Renal Disease Study Group (MDRD) calculation.

          -  Use of warfarin or amiodarone within 3 months prior to enrolment (screening) and use
             of potent CYP450 inhibitors, eg, ketoconazole and/or macrolide antibiotics within 14
             days before randomisation.
Clinical trial NCT00494091 (phase 2, status: completed)
Conditions: advanced renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: temsirolimus (cci-779), temsirolimus (cci-779)
SMILES: OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC, OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with histologically confirmed, advanced (stage IV or recurrent disease) RCC.
             The American Joint Committee on Cancer (AJCC) staging and classification criteria will
             be used.

          -  ECOG performance status of 0-1.

          -  At least one measurable lesion per RECIST.

          -  Age greater than or equal to 20 years.

          -  Japanese, Chinese, or Korean ethnicity.

        Exclusion Criteria:

          -  CNS metastases at screening or history or CNS metastases.

          -  Prior targeted, chemotherapeutic, cytokine-based, or other investigational agents for
             the treatment of RCC within 4 weeks before first dose of test article. Subjects must
             have documented objective progressive disease after any prior systemic RCC treatment
             and have recovered to grade 1 or lower toxicities from effects of prior systemic
             therapy for RCC.

          -  In past 5 years, other prior malignancy (except basal cell carcinoma, squamous cell
             carcinoma of the skin, or cervical carcinoma in situ).
Clinical trial NCT01043185 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: azd3355, azd3355, azd3355, azd3355, placebo
SMILES: NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provide informed consent

          -  History of GERD with persistent symptoms despite treatment with PPI

          -  Otherwise normal physical health

        Exclusion Criteria:

          -  History of GERD with symptoms that has not improved at all during treatment with PPI

          -  Prior surgery of the upper gastrointestinal tract

          -  History of significant heart disease, cardiovascular, respiratory, hepatic, renal,
             metabolic, psychiatric or gastrointestinal disorders besides GERD
Clinical trial NCT00335543 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: cisplatin, gemcitabine hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreatic head

               -  No tumors of the body or tail, as defined by a tumor lying between the left
                  border of the superior mesenteric vein and the left border of the aorta and/or
                  the left border of the aorta and the hilum of the spleen

          -  Locally resectable disease by CT scan

               -  Major vessels (e.g., portal vein, confluence of mesenteric and splenic vein,
                  superior mesenteric artery, celiac trunk, splenic artery, hepatic artery, or
                  superior mesenteric vein) maximally enclosed ≤ 180° by the tumor

          -  No infiltration of extrapancreatic organs except the duodenum

          -  No carcinoma of the ampulla of Vater

          -  No metastasis

          -  No peritoneal carcinoma

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Creatinine clearance > 70 mL/min

          -  Creatinine < 1.5 mg/dL

          -  Platelet count > 100,000/mm³

          -  No liver cirrhosis

          -  Not pregnant

          -  No New York Heart Association class III or IV heart disease

          -  No respiratory insufficiency

          -  No grade III or IV cardiac arrhythmias

          -  No pathology on EKG

          -  No other severe cardiopulmonary disease

          -  No HIV infection

          -  No other disease that renders the patient unsuitable for one treatment option

          -  No other malignancy except nonmelanoma skin cancer, carcinoma in situ of the cervix,
             or other cancer for which the patient was treated with surgery only and has been in
             complete remission for ≥ 10 years

        PRIOR CONCURRENT THERAPY:

          -  At least 3 months since prior participation in another clinical trial

          -  No prior or other concurrent treatment for carcinoma of the pancreas
Clinical trial NCT00427934 (phase 2, status: terminated)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: maraviroc, maraviroc placebo
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Reason stopped: 
    see detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must be legal age of consent

          -  Must have active rheumatoid arthritis based upon the American College of Rheumatology
             (ACR) 1987 (Revised Criteria); minimum disease criteria required for entry into the
             efficacy component of the study

          -  Must meet ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II,
             or III

          -  Must be receiving methotrexate for at least 12 weeks duration and on a stable dose for
             4 weeks.

        Exclusion Criteria:

          -  Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory
             arthritis that would interfere with disease activity assessments.

          -  Subject receiving prior treatment with certain medications for rheumatoid arthritis

          -  Tuberculosis and/or a positive tuberculin reaction

          -  Significant trauma or major surgery within 2 months

          -  History of alcohol and/or drug abuse outside of a defined period of abstinence

          -  History of or a finding at screening of postural hypotension

          -  Any condition that would affect the oral absorption of the drug

          -  History of cancer and in remission less than 3 years or Grade III-IV congestive heart
             failure

          -  Having an infection of human immunodeficiency virus (HIV), Hepatitis B or C or
             evidence of any active infection

          -  Abnormalities of clinical or laboratory assessments completed at the screening visit
             such as elevated liver enzymes, decreased hemoglobin or an abnormal ECG

          -  Having a positive chemokine receptor 5 (CCR5) delta 32 mutation

          -  Requiring the use of certain medications

          -  Lactating or pregnant women or subjects have reproductive potential unwilling to use
             an adequate method of birth control

          -  Chronic or recent serious or life-threatening infection; severe , progressive and/or
             uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary,
             cardiac, neurological disease within 12 weeks of the first dose.
Clinical trial NCT00087152 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine, imatinib mesylate
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        -  Histologically or cytologically confirmed adenocarcinoma of the breast

          -  Stage IV measurable disease

          -  Disease progression after at least 1, but no more than 2, prior chemotherapy regimens
             for metastatic disease

          -  Patients with hormone-sensitive tumors must have received prior hormonal therapy

          -  Patients with human epidermal growth factor receptor 2 (HER2)/neu-overexpressing
             tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization)
             should have received trastuzumab (Herceptin®) in the adjuvant or metastatic setting
             (unless contraindicated)

          -  No clinical evidence of or known brain or central nervous system (CNS) disease

          -  Hormone Receptor status known

          -  Female age 18 and over

          -  Performance status Zubrod 0-2

          -  Absolute neutrophil count > 1,500/mm^3

          -  Leukocyte count > 3,000/mm^3

          -  Platelet count > 100,000/mm^3

          -  Bilirubin normal

          -  aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 2.5 times upper
             limit of normal

          -  Creatinine normal OR Creatinine clearance > 60 mL/min

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 3 months after study
             participation

          -  No history of severe hypersensitivity reaction to compounds of similar chemical or
             biological composition to imatinib mesylate, capecitabine, or fluorouracil

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No prior biologic therapy (e.g., vaccines)

          -  No concurrent filgrastim (G-CSF) for chemotherapy-induced neutropenia

          -  No prior capecitabine or fluorouracil for metastatic breast cancer

          -  Prior hormonal therapy allowed

          -  More than 4 weeks since prior radiotherapy - Previously irradiated area(s) must not be
             the only site of disease

          -  More than 4 weeks since prior major surgery

          -  More than 4 weeks since prior therapy for breast cancer

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational or commercial agents or therapies for metastatic
             breast cancer
Clinical trial NCT00193453 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, docetaxel, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        To be included in the study, you must meet the following criteria:

          -  18 years of age or older

          -  Non-small cell lung cancer confirmed by biopsy

          -  Unresectable stage III or IV disease

          -  Measurable disease

          -  Must not have received any prior chemotherapy for lung cancer

          -  Able to perform activities of daily living without considerable assistance

          -  Adequate bone marrow, kidney, and liver function

          -  Signed informed consent

        Exclusion Criteria:

        You cannot participate in the study if any of the following apply to you:

          -  History of serious heart disease within six months prior to study entry

          -  Prior treatment with agents that target the EGFR pathway

          -  History of any other uncontrolled or significant disease

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have. You can then decide if you wish to
        participate.
Clinical trial NCT00654953 (phase 2, status: completed)
Conditions: cocaine dependence, depressive symptoms
ICD codes: F14.20, F14.24, F14.280, F14.281, F14.282, F14.288, F14.29, F33.3
Drugs: sertraline, placebo, gabapentin
SMILES: CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  18-65 years old

          -  not currently enrolled in a treatment program

          -  subjects must have a history of cocaine use, with street cocaine use by history being
             a minimum of 1 gram during the preceding 3 months

          -  subjects must meet DSM-IV criteria for cocaine dependence as assessed by the substance
             abuse section of the Structured Clinical Interview for DSM-IV (SCID and SCID-SAC)

          -  subjects must have laboratory confirmation of recent cocaine use (positive urine for
             cocaine or benzoylecgonine) during the month prior to study entry

          -  subjects must score at least 15 on the Hamilton Depression Scale

          -  women of childbearing age must have a negative pregnancy test to enroll in this study
             and must agree to monthly pregnancy testing

        Exclusion Criteria:

          -  current diagnosis of other drug or alcohol physical dependence (other than cocaine or
             tobacco)

          -  ill health (e.g., major cardiovascular, renal, endocrine, hepatic disorder)

          -  history of schizophrenia, or bipolar type I disorder

          -  present or recent use of over-the-counter or prescription psychoactive drug or drug(s)
             that would be expected to have major interaction with drug to be tested

          -  medical contraindication to receiving study medications (e.g., for sertraline, use of
             monoamine oxidase inhibitor within last two weeks; significant history of seizures;
             significant history of head trauma or serious neurological disorders)

          -  current suicidality or psychosis

          -  Liver function tests (i.e., liver enzymes) greater than three times normal levels

          -  pregnancy
Clinical trial NCT00525603 (phase 2, status: completed)
Conditions: leukemia, chronic lymphocytic leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C91.11, C91.12, C91.10
Drugs: cyclophosphamide, fludarabine, alemtuzumab, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of CLL by immunophenotyping and flow cytometry
             analysis of blood or bone marrow and be previously untreated.

          -  All patients must be younger than 70 years and have a serum beta-2 microglobulin of
             >/= 4.0mg/L.

          -  All patients with Rai stage III-IV are eligible for treatment on this protocol. - OR -
             All patients with Rai stage 0-II who meet one or more indication for treatment as
             defined by the NCI-sponsored Working Group are eligible for treatment on this
             protocol.

          -  All patients must have a Zubrod performance status of 0-3.

          -  All patients must have adequate renal and hepatic function (serum creatinine </=
             2mg/dL; total bilirubin </= 2.5mg/dL). Patients with renal or liver dysfunction due to
             organ infiltration by lymphocytes may be eligible after discussion with the Principle
             Investigator and appropriate dose adjustment considered.

          -  Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy.
             Localized radiotherapy to an area not compromising bone marrow function does not
             apply, nor do hematopoietic growth factors such as erythropoietin, Granulocyte
             colony-stimulating factor (G-CSF), Granulocyte-Macrophage Colony Stimulating Factor
             (GM-CSF), etc.

          -  Patients must not have untreated or uncontrolled life-threatening infection.

          -  Patients must sign informed consent.

        Exclusion Criteria:

        Patients older than 70 years.
Clinical trial NCT00494338 (phase 2, status: terminated)
Conditions: metastatic prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to celecoxib safety issues
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically confirmed MAIPC

          -  Documented progressive disease in bone, soft tissue or PSA despite castrate levels of
             testosterone

          -  If LHRH agonist were used previously it must be kept

          -  Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone
             and 6 weeks for bycalumida

          -  Previous DES should be held for at least 4 weeks before partcipating in the trial

          -  Chemotherapy naive patients

          -  No prior radioisotope

          -  Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy

          -  KPS> 70%

          -  Adequate hematologic, hepatic and renal function

        Exclusion Criteria:

          -  Patients with serious medical illness

          -  History of significant active cardiac disease

          -  History of gastrointestinal ulceration, bleeding or perforation

          -  History of myocardial infarctin within past 12 months

          -  Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.